SOMAÍ Pharmaceuticals (“SOMAÍ”), a leading EU-GMP European pharmaceutical and biotech company specialising in cannabinoid pharmaceuticals, has just announced its partnership with AIRO BRANDS, Inc. (“Airo”), a prominent U.S. multi-state consumer packaged goods (CPG) company renowned for its proprietary cannabis products.
Thanks to this strategic collaboration, SOMAÍ gains exclusive rights to manufacture and distribute Airo’s award-winning products in the medical markets of Australia, Germany, Poland, and Switzerland. Leveraging SOMAÍ’s expertise in manufacturing inhalation oils to the highest standards of safety and quality, the partnership aims to introduce Airo’s renowned products to European and Australian consumers starting in the second quarter of 2024.
Airo has established itself as a leading cannabis brand in the United States. It has a presence in 23 states and Puerto Rico. The brand is renowned for its premium vaporizer technologies. We can ditinguish here AiroPro, AiroSport, and AiroX, as well as its diverse range of AiroPod oil formulations, including Artisan, Strain, Live Flower, Live Resin, and Live Rosin. In addition to its vape portfolio, Airo recently launched ORIA. It is a line of cannabis-infused gummies, further solidifying its position as an innovator in the industry.
Comments about SOMAÍ and Airo development
Richard Yost, CEO of Airo commented:
“Expanding our brand globally is a significant achievement for Airo, and finding a partner who shares our dedication to quality and consumer focus was paramount. SOMAÍ stood out to us not only for its state-of-the-art facility in Portugal but also for the calibre of its team. It’s a perfect match,”
Michael Sassano, is a Founder and CEO of SOMAÍ Pharmaceuticals. He emphasised the importance of this partnership in propelling Airo’s products into the international market.
“As leading U.S. companies set their sights on Europe, Airo is at the forefront of global expansion. With SOMAÍ’s commitment to EU-GMP quality standards, our partnership ensures that Airo’s product offerings will reach consumers worldwide. As global markets continue to evolve, we are proud to bring Airo’s best-in-class vaporizers to consumers across Europe and beyond.”
With the European and Australian markets embracing the burgeoning cannabis industry, SOMAÍ Pharmaceuticals’ collaboration with Airo Brands represents a significant opportunity to introduce innovative and high-quality cannabis products to a broader audience. Year 2023 was very successful for SOMAÍ especially, as Michael Sassano described in our last interview. Both companies share a commitment to excellence and consumer satisfaction. Thus, this partnership is poised to drive growth and success in the rapidly evolving global cannabis market.